Mundipharma Partners With Samsung Bioepis For Hong Kong And Taiwan
Partnership Covers Adalimumab, Etanercept, Trastuzumab and Bevacizumab
Mundipharma and Samsung Bioepis are undertaking an exclusive commercialization partnership for a portfolio of biosimilars in Hong Kong and Taiwan.
You may also be interested in...
Mundipharma has struck a deal with Prestige BioPharma for rights to the Singapore-based firm’s biosimilar trastuzumab in selected European markets.
Mundipharma is entering into a partnership with Egis for launching its pegfilgrastim biosimilar treatment in Hungary, Romania, Latvia and Lithuania.
Armas has kicked off 2020 with the launch of four generic injectables in the US.